Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aftobetin-HCl and Sapphire II for Beta-Amyloid Detection in Alzheimer's
NCT02928211Phase 1Unknown
- Sponsor
- Cognoptix
- Start
- Jul 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aftobetin in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Cognoptix. Primary endpoints: Paired pre-ligand and post ligand fluorescent uptake values at 4 weeks, Determination of success at 4 weeks and 1 more. Status: unknown.
02
Drugs
aftobetin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02928211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928211.